Accéder au contenu
Merck

RAGE overexpression confers a metastatic phenotype to the WM115 human primary melanoma cell line.

Biochimica et biophysica acta (2014-03-13)
Varsha Meghnani, Stefan W Vetter, Estelle Leclerc
RÉSUMÉ

The formation of melanoma metastases from primary tumor cells is a complex phenomenon that involves the regulation of multiple genes. We have previously shown that the receptor for advanced glycation end products (RAGE) was up-regulated in late metastatic stages of melanoma patient samples and we hypothesized that up-regulation of RAGE in cells forming a primary melanoma tumor could contribute to the metastatic switch of these cells. To test our hypothesis, we overexpressed RAGE in the WM115 human melanoma cell line that was established from a primary melanoma tumor of a patient. We show here that overexpression of RAGE in these cells is associated with mesenchymal-like morphologies of the cells. These cells demonstrate higher migration abilities and reduced proliferation properties, suggesting that the cells have switched to a metastatic phenotype. At the molecular level, we show that RAGE overexpression is associated with the up-regulation of the RAGE ligand S100B and the down-regulation of p53, ERK1/2, cyclin E and NF-kB. Our study supports a role of RAGE in the metastatic switch of melanoma cells.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Roche
Réactif de transfection d'ADN X-tremeGENE 9, Polymer reagent for transfecting common cell lines
Sigma-Aldrich
Iodure de propidium, ≥94.0% (HPLC)
Sigma-Aldrich
Sulforhodamine 101, Dye content ~95 %
Sigma-Aldrich
Iodure de propidium solution
Sigma-Aldrich
Iodure de propidium, ≥94% (HPLC)